© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Aging baby boomers make up the greatest demand for hepatitis C-related liver transplantations in the United States.
Abbott has announced Phase III trials of three direct acting agents, ABT-450/r, ABT-267, ABT-333, which together have shown high cure rates in...
Entecavir has shown safety and efficacy over a five-year period in people with hepatitis B who haven’t yet tried treatment with nucleos(t)ide...
Investigational agents daclatasvir and asunaprevir have shown high cure rates among prior null-responders with difficult-to-treat strains of h...
Antiviral therapies faldaprevir and BI 207127 are safe and effective among people with hepatitis C virus, including those with advanced liver...
Tenofovir is safe and effective for long-term treatment of hepatitis B, and leads to few kidney-related side effects and no clinically relevan...
Spanish researchers have sounded the alarm that rates of liver cancer are rising dramatically among people with HIV, solely as a result of vir...
The new therapy simeprevir is generally safe and well-tolerated among hep C patients with advanced liver fibrosis and improves treatment outco...
A combination of daclatasvir and sofosbuvir produced cures in more than 93 percent of hepatitis C patients, with or without the addition of ri...
Danoprevir and mericitabine, two experimental hepatitis C therapies, proved safe and effective among patients with previous treatment experien...
Bristol-Myers Squibb?s triple combination hepatitis C therapy showed a 94 percent cure rate in hard-to-treat patients.
People coinfected with HIV and hepatitis C virus experience high hepatitis cure rates from an Incivek (telaprevir)-based triple combination th...
Gilead Sciences? pair of investigatory hepatitis C virus therapies led to a 100 percent cure rate among a small cohort of patients.
Abbott Laboratories’ three-drug regimen cured 97 percent of treatment-naive hepatitis C patients and 93 percent of those who had failed a prev...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.